Get the Stockscreener App
148.09
0.41%
0.60
Krystal Biotech Inc stock is traded at $148.09, with a volume of 163.78K.
It is up +0.41% in the last 24 hours and up +11.80% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$147.49
Open:
$148
24h Volume:
163.78K
Relative Volume:
0.46
Market Cap:
$4.28B
Revenue:
$290.51M
Net Income/Loss:
$89.16M
P/E Ratio:
49.53
EPS:
2.99
Net Cash Flow:
$119.18M
1W Performance:
-1.54%
1M Performance:
+11.80%
6M Performance:
-2.28%
1Y Performance:
-27.29%
1-Day Range:
$147.03
$150.49
1-Week Range:
$146.35
$153.74
52-Week Range:
$122.80
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
148.09 | 4.35B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
What analysts say about Krystal Biotech Inc. stockExceptional trading results - jammulinksnews.com
What drives Krystal Biotech Inc. stock priceMarket-leading capital gains - Autocar Professional
Is Krystal Biotech Inc. a good long term investmentUnprecedented growth rates - Autocar Professional
Krystal Biotech Inc. Stock Analysis and ForecastFree Advanced Stock Screener Access - Jammu Links News
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Nisa Investment Advisors LLC - Defense World
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Hedge Fund and Insider Trading News: Bobby Jain, Bill Ackman, Ken Griffin, Sylebra Capital Management, Millennium Management, Krystal Biotech Inc (KRYS), and More - Insider Monkey
William Blair Predicts Lower Earnings for Krystal Biotech - Defense World
Krishnan Krish S, Krystal Biotech CEO, sells $5.39 million in stock - Investing.com Canada
Krystal biotech (KRYS) director Suma Krishnan sells $5.39m in stock By Investing.com - Investing.com South Africa
Krystal biotech (KRYS) director Suma Krishnan sells $5.39m in stock - Investing.com Australia
Krystal Biotech, Inc. (NASDAQ:KRYS) Position Trimmed by Bank of New York Mellon Corp - Defense World
why krystal biotech inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser
M&T Bank Corp Purchases New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech FY2025 EPS Estimate Lowered by William Blair - Defense World
Why Krystal Biotech Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
How Krystal Biotech Inc. stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
What makes Krystal Biotech Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times
Teacher Retirement System of Texas Has $1.05 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
William Blair Forecasts Lower Earnings for Krystal Biotech - Defense World
William Blair Expects Lower Earnings for Krystal Biotech - Defense World
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up - Yahoo Finance
Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK By Investing.com - Investing.com South Africa
Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK - Investing.com Nigeria
Transcript : Krystal Biotech, Inc.Special Call - MarketScreener
Krystal Biotech Begins Phase 1/2 Trial for KB801 - TipRanks
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis - The Manila Times
Krystal Biotech Initiates First Patient Dosing in Phase 1/2 EMERALD-1 Trial for KB801 in Neurotrophic Keratitis - Nasdaq
Revolutionary Eye Drop Gene Therapy: Krystal Biotech Targets 68,000 Patient NK Market in New Trial - Stock Titan
New York State Teachers Retirement System Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Allspring Global Investments Holdings LLC Decreases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Amalgamated Bank - Defense World
Vontobel Holding Ltd. Sells 284 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Exploring High Growth Tech Stocks In The US Market - Yahoo Finance
Long Term Trading Analysis for (KRYS) - news.stocktradersdaily.com
GAMMA Investing LLC Acquires 432 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):